Log in

NYSE:MRK - Merck & Co., Inc. Stock Price, Forecast & News

$82.65
+0.68 (+0.83 %)
(As of 02/17/2020 01:00 AM ET)
Add
Today's Range
$81.67
Now: $82.65
$82.80
50-Day Range
$81.97
MA: $88.51
$92.07
52-Week Range
$72.23
Now: $82.65
$92.64
Volume8.34 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio21.69
Dividend YieldN/A
BetaN/A
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
CUSIP58933Y10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees69,000
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.


Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Wednesday, January 29th. Stockholders of record on Monday, March 16th will be paid a dividend of $0.61 per share on Tuesday, April 7th. This represents a $2.44 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Friday, March 13th. View Merck & Co., Inc.'s Dividend History.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. announced that its board has approved a share repurchase plan on Thursday, October 25th 2018, which authorizes the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 5.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board of directors believes its shares are undervalued.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Wednesday, February, 5th. The company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.01. The business earned $11.87 billion during the quarter, compared to analyst estimates of $11.71 billion. The company's quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.04 earnings per share. View Merck & Co., Inc.'s Earnings History.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Merck & Co., Inc..

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided earnings per share guidance of $5.62-5.77 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.54. The company issued revenue guidance of $48.8-50.3 billion, compared to the consensus revenue estimate of $48.65 billion.

What price target have analysts set for MRK?

16 brokers have issued 1 year target prices for Merck & Co., Inc.'s stock. Their forecasts range from $84.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $95.93 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price. View Analyst Price Targets for Merck & Co., Inc..

What is the consensus analysts' recommendation for Merck & Co., Inc.?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merck & Co., Inc..

What are Wall Street analysts saying about Merck & Co., Inc. stock?

Here are some recent quotes from research analysts about Merck & Co., Inc. stock:
  • 1. Mizuho analysts commented, "We like shares of MRK driven by KEYTRUDA’s penetration of global markets in multiple indications, which we believe will drive P&L transformation. While KEYTRUDA is growing in dominance, both in the market and on MRK’s P&L, we see MRK as having considerable runway (2028 LOE) to address concerns regarding concentration of revenue." (9/8/2019)
  • 2. According to Zacks Investment Research, "Merck’s new products like Keytruda, Lynparza, and Bridion are contributing meaningfully to the top line. Keytruda sales are gaining momentum with approval for additional indications, especially in the first-line lung cancer setting. Keytruda has strong growth prospects based on increased utilization, recent approvals for new indications and potential additional approvals worldwide. Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck. The company will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and products like Isentress (HIV), Zepatier (HCV) and Zostavax (vaccine) remains a concern. Merck’s shares have outperformed the industry this year. " (4/1/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate MRK 12-month PT of $95. We think there is upside to Keytruda sales estimates. Sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin-expansion opportunities, are underappreciated, in our view. Therefore, we expect upward earnings revisions and multiple expansion in 2019+ to drive MRK’s shares higher. Valuation Summary We arrive at our 12-month price target of $95 for Merck shares by using a blend of Base case analyses." (3/29/2019)

Has Merck & Co., Inc. been receiving favorable news coverage?

Media stories about MRK stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck & Co., Inc. earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Merck & Co., Inc..

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Walt Disney (DIS), Intel (INTC), Cisco Systems (CSCO), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Exxon Mobil (XOM).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the folowing people:
  • Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 64)
  • Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 52)
  • Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 41)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
  • Mr. Adam H. Schechter, Special Advisor (Age 54)

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (4.58%), Bank of New York Mellon Corp (1.37%), Franklin Resources Inc. (0.67%), UBS Asset Management Americas Inc. (0.53%), FMR LLC (0.49%) and Charles Schwab Investment Management Inc. (0.47%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., GQG Partners LLC, Victory Capital Management Inc., Bank of New York Mellon Corp, DekaBank Deutsche Girozentrale, PGGM Investments, Pzena Investment Management LLC and FIL Ltd. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca and Robert M Davis. View Insider Buying and Selling for Merck & Co., Inc..

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Assenagon Asset Management S.A., State Street Corp, Stifel Financial Corp, FMR LLC, Van ECK Associates Corp, MERIAN GLOBAL INVESTORS UK Ltd and MERIAN GLOBAL INVESTORS UK Ltd. View Insider Buying and Selling for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $82.65.


MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  827 (Vote Outperform)
Underperform Votes:  817 (Vote Underperform)
Total Votes:  1,644
MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel